209 related articles for article (PubMed ID: 16457153)
1. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor.
Shi M; Su L; Hao S; Guo X; Xiang J
Tumori; 2005; 91(6):531-8. PubMed ID: 16457153
[TBL] [Abstract][Full Text] [Related]
2. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
3. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity.
Liu Y; Zhang W; Chan T; Saxena A; Xiang J
Leuk Res; 2002 Aug; 26(8):757-63. PubMed ID: 12191571
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell/myeloma hybrid vaccine.
Xia D; Chan T; Xiang J
Methods Mol Med; 2005; 113():225-33. PubMed ID: 15968106
[TBL] [Abstract][Full Text] [Related]
6. [Induction of Th1 immune response against tumor by genetically engineered fusion of tumor cells and dendritic cells].
Zhang W; Yang H; Zeng H; Chen Z
Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):61-4. PubMed ID: 12015071
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
8. Enhancing antitumor by immunization with fusion of dendritic cells and engineered tumor cells.
Zhang W; Yang H; Zeng H
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(1):1-4. PubMed ID: 12658768
[TBL] [Abstract][Full Text] [Related]
9. Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses.
Shi M; Hao S; Su L; Zhang X; Yuan J; Guo X; Zheng C; Xiang J
Cancer Biother Radiopharm; 2005 Aug; 20(4):401-9. PubMed ID: 16114988
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
[TBL] [Abstract][Full Text] [Related]
12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
13. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
Liu Y; Qureshi M; Xiang J
Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
[TBL] [Abstract][Full Text] [Related]
14. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
Yasuda T; Kamigaki T; Kawasaki K; Nakamura T; Yamamoto M; Kanemitsu K; Takase S; Kuroda D; Kim Y; Ajiki T; Kuroda Y
Cancer Immunol Immunother; 2007 Jul; 56(7):1025-36. PubMed ID: 17131118
[TBL] [Abstract][Full Text] [Related]
15. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70.
Xie Y; Bai O; Zhang H; Yuan J; Zong S; Chibbar R; Slattery K; Qureshi M; Wei Y; Deng Y; Xiang J
J Cell Mol Med; 2010 Nov; 14(11):2655-66. PubMed ID: 19627400
[TBL] [Abstract][Full Text] [Related]
16. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
19. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
[TBL] [Abstract][Full Text] [Related]
20. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
